Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FORADIL vs AEROLATE III
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Formoterol is a long-acting beta2-adrenergic receptor agonist (LABA) that relaxes bronchial smooth muscle by increasing intracellular cyclic AMP.
AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.
Long-term maintenance treatment of asthma,Prevention of exercise-induced bronchospasm,Maintenance treatment of chronic obstructive pulmonary disease (COPD)
Treatment and prophylaxis of bronchospasm associated with asthma, chronic bronchitis, and emphysema,Off-label: Apnea of prematurity (oral/IV theophylline)
Inhalation: 12 mcg twice daily (every 12 hours) via Foradil Aerolizer.
Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.
Terminal half-life: 7-10 hours. Steady-state achieved within 3-5 days; clinical context: allows twice-daily dosing for bronchodilation.
Terminal half-life 12-15 hours; clinically allows twice-daily dosing
Metabolized primarily by hepatic glucuronidation and to a lesser extent by CYP2D6, CYP2C19, and CYP2C9.
Primarily hepatic via cytochrome P450 1A2 (CYP1A2); also CYP2E1 and CYP3A4; exhibits nonlinear pharmacokinetics.
Renal (60% as unchanged drug and metabolites) and fecal (40% as metabolites).
Renal: 60% unchanged; biliary/fecal: 30% as metabolites; 10% other
61% bound to plasma proteins, primarily albumin.
92-96%, primarily to albumin and alpha-1-acid glycoprotein
6.0 L/kg (extensive tissue distribution, indicating high penetration into lungs and peripheral tissues).
Vd 1.5-2.0 L/kg, indicating extensive tissue distribution
Inhalation: ~30% (systemic absorption from lungs; oral bioavailability negligible due to first-pass metabolism).
Oral: 40-50%; Inhalation: 20-30%
No dose adjustment required for renal impairment.
No adjustment needed for GFR >30 m L/min. For GFR 10-30 m L/min: use 50% of usual dose. For GFR <10 m L/min: avoid use.
No specific dose adjustment recommended; use caution in severe hepatic impairment.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use.
Children 5 years and older: 12 mcg inhalation twice daily. No dosing established for children under 5 years.
Children 2-11 years: 1 inhalation (100 mcg) twice daily via metered-dose inhaler. Children 12 years and older: same as adult.
No specific dose adjustment; monitor for adverse effects due to potential comorbidities.
No specific dose adjustment but monitor for increased systemic effects; start at lowest effective dose.
LABAs increase the risk of asthma-related death; Foradil should only be used in patients with asthma not adequately controlled on asthma controller medications or whose disease severity warrants initiation of both an inhaled corticosteroid and a LABA.
No FDA black box warning.
Increased risk of asthma-related death,Deterioration of disease and acute episodes may occur and should be treated with a short-acting beta2-agonist,Cardiovascular effects (increased heart rate, blood pressure, ECG changes),Hypokalemia and hyperglycemia may occur,Paradoxical bronchospasm may occur and require immediate discontinuation,Do not use with other LABAs
Monitor serum theophylline concentrations due to narrow therapeutic index; risk of toxicity at levels >20 mcg/m L; use caution in patients with cardiac disease, hepatic impairment, or seizures; may exacerbate arrhythmias; drug interactions with cimetidine, fluoroquinolones, macrolides, allopurinol, oral contraceptives, smoking, and others.
Hypersensitivity to formoterol or any ingredient in the formulation,Use as monotherapy in asthma without concomitant inhaled corticosteroid,Treatment of acute asthma symptoms or exacerbations
Hypersensitivity to theophylline or any component; pre-existing cardiac arrhythmias (e.g., ventricular tachycardia); recent myocardial infarction; uncontrolled seizure disorders.
No specific food interactions. Grapefruit/grapefruit juice may increase systemic exposure via CYP3A4 inhibition; avoid concurrent use.
Avoid significant intake of caffeine-containing foods/beverages (coffee, tea, cola, chocolate) as they may increase CNS stimulation and risk of toxicity. Charcoal-broiled foods and a high-protein diet may increase clearance. Maintain consistent dietary patterns; avoid extremes of protein/carbohydrate intake.
FDA Pregnancy Category C. In animal studies, formoterol fumarate (active ingredient of FORADIL) showed adverse effects on fetal development at high doses, including increased fetal loss, decreased fetal weight, and skeletal variations. There are no adequate and well-controlled studies in pregnant women. During first trimester, risk cannot be ruled out. Second and third trimesters: potential risk of maternal beta-agonist effects causing uterine relaxation and delayed labor. Use only if potential benefit justifies potential risk to fetus.
AEROLATE III (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be ruled out. Second/third trimesters: Increased fetal heart rate, jitteriness, and risk of neonatal apnea with high maternal serum concentrations (>15 mcg/m L). Avoid near term due to prolonged neonatal half-life.
Formoterol is excreted in human milk in small amounts. M/P ratio not established. Caution should be exercised when administered to nursing women. Consider the developmental and health benefits of breastfeeding along with the mother's clinical need for FORADIL and any potential adverse effects on the breastfed infant from the drug or underlying maternal condition.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.7. Infant serum levels can reach 50% of maternal levels; risk of irritability and sleep disturbances in nursing infants. Use with caution and monitor infant for signs of toxicity.
No specific dose adjustments are recommended for FORADIL during pregnancy based on pharmacokinetic changes. However, use the lowest effective dose to control asthma symptoms. Monitor for potential increased need for rescue medication due to pregnancy-related changes in asthma severity. No data indicate significant pharmacokinetic changes requiring dosing modification.
Pregnancy may increase theophylline clearance due to enhanced hepatic metabolism and increased renal blood flow. Dose adjustments are often required: monitor serum levels regularly and adjust dose to maintain therapeutic levels. Typically, dose may need to be increased by 20-50% in second and third trimesters.
FORADIL (formoterol fumarate) is a long-acting beta2-agonist (LABA) indicated for maintenance treatment of asthma and COPD, but must not be used as monotherapy for asthma without concomitant inhaled corticosteroid. Onset of bronchodilation occurs within 5-10 minutes, peaking at 1-3 hours, with duration up to 12 hours. Not for acute bronchospasm. Risk of paradoxical bronchospasm; discontinue if occurs. Monitor for increased heart rate, blood pressure, and QTc prolongation. Caution in patients with cardiovascular disorders, seizure disorders, thyrotoxicosis, or diabetes.
AEROLATE III (theophylline) is a bronchodilator with a narrow therapeutic index; monitor serum levels (target 10-20 mcg/m L). Caffeine and smoking increase clearance; hepatic impairment, heart failure, and certain drugs (e.g., cimetidine, fluoroquinolones) decrease clearance. Avoid use in patients with active peptic ulcer or seizure disorders. Titrate dose slowly to minimize nausea, vomiting, and arrhythmias.
Use FORADIL exactly as prescribed; do not use to relieve sudden breathing problems.,Always have a fast-acting rescue inhaler (e.g., albuterol) for acute symptoms.,Do not use more than 2 inhalations every 12 hours; maximum daily dose is 48 mcg.,Rinse mouth with water after each use to reduce risk of thrush (if using with ICS).,Seek medical help immediately if breathing worsens, chest tightness, or hives develop.,Inform your doctor if you have heart disease, high blood pressure, seizures, thyroid problems, or diabetes.,Store capsules in blister pack, use only with provided Aerolizer inhaler; do not swallow capsules.
Take this medication exactly as prescribed; do not crush or chew extended-release tablets.,Avoid consuming large amounts of caffeine (coffee, tea, chocolate) as it may increase side effects like jitteriness and insomnia.,Inform your doctor if you experience nausea, vomiting, rapid heartbeat, or seizures.,Do not stop taking this medication abruptly; taper under medical supervision.,Keep all appointments for blood tests to monitor theophylline levels.,Avoid smoking or using nicotine products, as they affect how the medication works.,Carry a list of all medications you take, as many can interact with theophylline.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FORADIL vs AEROLATE III, answered by our medical review team.
FORADIL is a Bronchodilator that works by Formoterol is a long-acting beta2-adrenergic receptor agonist (LABA) that relaxes bronchial smooth muscle by increasing intracellular cyclic AMP.. AEROLATE III is a Bronchodilator that works by AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FORADIL and AEROLATE III depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FORADIL is: Inhalation: 12 mcg twice daily (every 12 hours) via Foradil Aerolizer.. The standard adult dose of AEROLATE III is: Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FORADIL and AEROLATE III in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FORADIL is classified as Category C. FDA Pregnancy Category C. In animal studies, formoterol fumarate (active ingredient of FORADIL) showed adverse effects on fetal development at high doses, including increased fetal. AEROLATE III is classified as Category C. AEROLATE III (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be ruled out. Second/third trimesters: Increased fetal h. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.